Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-351 in Glaucoma or Ocular Hypertension
NCT04448223Phase 2Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of latanoprost + dorzolamide in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
latanoprost + dorzolamide
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT04448223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04448223.